Valuation: Lexicon Pharmaceuticals, Inc.

Market Cap 1.04B 903M 846M 771M 1.45B 99.37B 1.47B 9.96B 3.89B 49.74B 3.91B 3.82B 166B P/E 2026 *
-14x
P/E 2027 * -12.5x
Enterprise Value 1.04B 903M 846M 771M 1.45B 99.37B 1.47B 9.96B 3.89B 49.74B 3.91B 3.82B 166B EV / Sales 2026 *
27.4x
EV / Sales 2027 * 52.3x
Free-Float
98.45%
Yield 2026 *
-
Yield 2027 * -
1 day-0.43%
1 week-0.85%
Current month+1.30%
1 month+7.83%
3 months-4.10%
6 months+78.63%
Current year+103.48%
1 week 2.31
Extreme 2.31
2.49
1 month 1.96
Extreme 1.96
2.52
Current year 1.1
Extreme 1.1
2.68
1 year 1.03
Extreme 1.03
2.68
3 years 0.28
Extreme 0.2836
3.73
5 years 0.28
Extreme 0.2836
6.33
10 years 0.28
Extreme 0.2836
19.62
Manager TitleAgeSince
Chief Executive Officer 56 08/07/2024
Director of Finance/CFO 59 02/01/2025
Chief Tech/Sci/R&D Officer - 01/02/2025
Director TitleAgeSince
Chairman 83 01/01/2005
Chairman 71 27/02/2012
Director/Board Member 67 28/08/2007
Date Insider Type Main position Quantity % Market Cap.
2/28/26 A Fiscal year

General Counsel

651,031 0.1792%
2/28/26 A Fiscal year

Chief Executive Officer

1,211,357 0.3333%
2/28/26 A Fiscal year

Chief Financial Officer

375,355 0.1033%
Change 5-day change 1-year change 3-year change Capi.($)
-0.43%-0.85%+110.81%+35.26% 1.04B
+2.07%+13.76%+65.44%+106.53% 71.56B
-2.09%-3.22%+32.70%+61.58% 54.43B
-4.50%-4.69%+2.82%+463.22% 27.59B
-1.27%-1.57%+46.46%+6.09% 23.91B
-0.67%+1.02%-18.32%-13.84% 23.14B
+0.44%+1.65%+39.32%-19.84% 18.65B
+0.35%+12.02%+257.19%+466.50% 18.64B
-0.95%-3.52%+20.04%+613.01% 16.01B
+0.46%-3.05%+31.49%+135.18% 12.54B
Average -0.66%+3.57%+58.79%+185.37% 26.75B
Weighted average by Cap. -0.49%+3.62%+50.79%+162.43%

Financials

2026 *2027 *
Net sales 37.95M 32.89M 30.83M 28.11M 52.9M 3.62B 53.75M 363M 142M 1.81B 142M 139M 6.05B 19.91M 17.26M 16.18M 14.75M 27.76M 1.9B 28.21M 191M 74.38M 951M 74.76M 73.14M 3.17B
Net income -72.44M -62.79M -58.86M -53.67M -101M -6.91B -103M -693M -271M -3.46B -272M -266M -11.54B -90.96M -78.85M -73.91M -67.39M -127M -8.68B -129M -870M -340M -4.35B -342M -334M -14.5B
Net Debt - -
Logo Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is engaged in research and development of drug candidates and the commercialization of the drug, INPEFA (sotagliflozin). INPEFA reduces the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease (CKD), and other cardiovascular risk factors. Sotagliflozin is an orally delivered small molecule drug candidate as a treatment for hypertrophic cardiomyopathy (HCM) and conducts the SONATA-HCM pivotal Phase 3 clinical trial of sotagliflozin in that indication. The Company develops pilavapadin, an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. The Company also develops LX9851, an orally delivered small molecule drug candidate, for the treatment of obesity and associated cardiometabolic disorders.
Employees
81
Date Price Change Volume
13/08/26 $2.340 -0.43% 2,315,188
12/08/26 $2.350 -3.29% 2,569,147
11/08/26 $2.430 +1.25% 3,031,984
10/08/26 $2.400 -2.83% 2,696,711
07/08/26 $2.470 +4.66% 3,085,741
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
2.340USD
Average target price
3.856USD
Spread / Average Target
+64.79%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LXRX Stock